vs

Side-by-side financial comparison of GLOBUS MEDICAL INC (GMED) and Primo Brands Corp (PRMB). Click either name above to swap in a different company.

Primo Brands Corp is the larger business by last-quarter revenue ($1.6B vs $826.4M, roughly 2.0× GLOBUS MEDICAL INC). GLOBUS MEDICAL INC runs the higher net margin — 17.0% vs 1.7%, a 15.3% gap on every dollar of revenue. On growth, GLOBUS MEDICAL INC posted the faster year-over-year revenue change (25.7% vs 0.8%). Over the past eight quarters, Primo Brands Corp's revenue compounded faster (19.7% CAGR vs 16.7%).

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Primo Brands Corporation is an American-Canadian water company offering multi-gallon bottled water, water dispensers, self-service refill water machines, and water filtration appliances. The company is headquartered in Tampa, Florida, and services residential and commercial customers across the United States, Canada, Europe and Israel.

GMED vs PRMB — Head-to-Head

Bigger by revenue
PRMB
PRMB
2.0× larger
PRMB
$1.6B
$826.4M
GMED
Growing faster (revenue YoY)
GMED
GMED
+25.0% gap
GMED
25.7%
0.8%
PRMB
Higher net margin
GMED
GMED
15.3% more per $
GMED
17.0%
1.7%
PRMB
Faster 2-yr revenue CAGR
PRMB
PRMB
Annualised
PRMB
19.7%
16.7%
GMED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
GMED
GMED
PRMB
PRMB
Revenue
$826.4M
$1.6B
Net Profit
$140.6M
$27.3M
Gross Margin
68.4%
28.6%
Operating Margin
20.5%
8.5%
Net Margin
17.0%
1.7%
Revenue YoY
25.7%
0.8%
Net Profit YoY
430.4%
-4.9%
EPS (diluted)
$1.01
$0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GMED
GMED
PRMB
PRMB
Q1 26
$1.6B
Q4 25
$826.4M
$1.6B
Q3 25
$769.0M
$1.8B
Q2 25
$745.3M
$1.7B
Q1 25
$598.1M
$1.6B
Q4 24
$657.3M
Q3 24
$625.7M
$0
Q2 24
$629.7M
$1.3B
Net Profit
GMED
GMED
PRMB
PRMB
Q1 26
$27.3M
Q4 25
$140.6M
$-13.0M
Q3 25
$119.0M
$16.8M
Q2 25
$202.8M
$27.6M
Q1 25
$75.5M
$28.7M
Q4 24
$26.5M
Q3 24
$51.8M
$-2.0K
Q2 24
$31.8M
$54.5M
Gross Margin
GMED
GMED
PRMB
PRMB
Q1 26
28.6%
Q4 25
68.4%
27.7%
Q3 25
67.2%
29.9%
Q2 25
66.6%
31.3%
Q1 25
67.3%
32.3%
Q4 24
59.9%
Q3 24
56.8%
Q2 24
58.7%
32.7%
Operating Margin
GMED
GMED
PRMB
PRMB
Q1 26
8.5%
Q4 25
20.5%
1.2%
Q3 25
17.9%
8.3%
Q2 25
10.2%
6.5%
Q1 25
16.2%
9.5%
Q4 24
9.2%
Q3 24
7.7%
Q2 24
7.9%
12.1%
Net Margin
GMED
GMED
PRMB
PRMB
Q1 26
1.7%
Q4 25
17.0%
-0.8%
Q3 25
15.5%
1.0%
Q2 25
27.2%
1.6%
Q1 25
12.6%
1.8%
Q4 24
4.0%
Q3 24
8.3%
Q2 24
5.0%
4.1%
EPS (diluted)
GMED
GMED
PRMB
PRMB
Q1 26
$0.07
Q4 25
$1.01
$-0.03
Q3 25
$0.88
$0.04
Q2 25
$1.49
$0.07
Q1 25
$0.54
$0.08
Q4 24
$0.19
Q3 24
$0.38
$-20.00
Q2 24
$0.23
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GMED
GMED
PRMB
PRMB
Cash + ST InvestmentsLiquidity on hand
$557.2M
Total DebtLower is stronger
$5.2B
Stockholders' EquityBook value
$4.6B
$3.0B
Total Assets
$5.3B
$10.6B
Debt / EquityLower = less leverage
1.74×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GMED
GMED
PRMB
PRMB
Q1 26
Q4 25
$557.2M
$376.7M
Q3 25
$18.8M
Q2 25
Q1 25
Q4 24
$890.1M
Q3 24
$71.9M
Q2 24
$82.5M
Total Debt
GMED
GMED
PRMB
PRMB
Q1 26
$5.2B
Q4 25
$5.2B
Q3 25
$5.1B
Q2 25
$5.1B
Q1 25
$5.0B
Q4 24
Q3 24
Q2 24
Stockholders' Equity
GMED
GMED
PRMB
PRMB
Q1 26
$3.0B
Q4 25
$4.6B
$3.0B
Q3 25
$4.4B
$3.2B
Q2 25
$4.3B
$3.2B
Q1 25
$4.1B
$3.3B
Q4 24
$4.2B
Q3 24
$4.1B
$-2.0K
Q2 24
$4.0B
$-296.8M
Total Assets
GMED
GMED
PRMB
PRMB
Q1 26
$10.6B
Q4 25
$5.3B
$10.6B
Q3 25
$5.1B
$11.0B
Q2 25
$5.0B
$11.0B
Q1 25
$4.7B
$11.0B
Q4 24
$5.3B
Q3 24
$5.1B
$0
Q2 24
$5.0B
Debt / Equity
GMED
GMED
PRMB
PRMB
Q1 26
1.74×
Q4 25
1.72×
Q3 25
1.61×
Q2 25
1.57×
Q1 25
1.51×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GMED
GMED
PRMB
PRMB
Operating Cash FlowLast quarter
$248.6M
$103.8M
Free Cash FlowOCF − Capex
$202.4M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
5.6%
2.9%
Cash ConversionOCF / Net Profit
1.77×
3.80×
TTM Free Cash FlowTrailing 4 quarters
$588.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GMED
GMED
PRMB
PRMB
Q1 26
$103.8M
Q4 25
$248.6M
$203.1M
Q3 25
$249.7M
$283.4M
Q2 25
$77.9M
$155.0M
Q1 25
$177.3M
$38.8M
Q4 24
$210.3M
Q3 24
$203.7M
$0
Q2 24
$54.3M
$102.5M
Free Cash Flow
GMED
GMED
PRMB
PRMB
Q1 26
Q4 25
$202.4M
$57.3M
Q3 25
$213.9M
$167.7M
Q2 25
$31.3M
$101.1M
Q1 25
$141.2M
$-23.2M
Q4 24
$193.2M
Q3 24
$161.7M
Q2 24
$26.5M
$61.4M
FCF Margin
GMED
GMED
PRMB
PRMB
Q1 26
Q4 25
24.5%
3.7%
Q3 25
27.8%
9.5%
Q2 25
4.2%
5.8%
Q1 25
23.6%
-1.4%
Q4 24
29.4%
Q3 24
25.8%
Q2 24
4.2%
4.7%
Capex Intensity
GMED
GMED
PRMB
PRMB
Q1 26
2.9%
Q4 25
5.6%
9.4%
Q3 25
4.7%
6.6%
Q2 25
6.2%
3.1%
Q1 25
6.0%
3.8%
Q4 24
2.6%
Q3 24
6.7%
Q2 24
4.4%
3.1%
Cash Conversion
GMED
GMED
PRMB
PRMB
Q1 26
3.80×
Q4 25
1.77×
Q3 25
2.10×
16.87×
Q2 25
0.38×
5.62×
Q1 25
2.35×
1.35×
Q4 24
7.94×
Q3 24
3.93×
Q2 24
1.71×
1.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GMED
GMED

Other$391.8M47%
Nevro Merger Agreement$293.6M36%
Enabling Technologies$141.0M17%

PRMB
PRMB

Regional spring water$801.2M49%
Purified water$511.2M31%
Other$208.2M13%
Premium water$105.5M6%

Related Comparisons